Corrigendum to "Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study" [Schizophr. Res. 239 (2022) 83-91].

Filts, Yuriy; Litman, Robert E; Martínez, Javier; Anta, Lourdes; Naber, Dieter; Correll, Christoph U

Filts, Yuriy; Litman, Robert E; Martínez, Javier; Anta, Lourdes; Naber, Dieter; Correll, Christoph U.

Affiliation

Filts Y; Communal Noncommercial Enterprise of Lviv Regional Council, Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine.
Litman RE; CBH Health LLC, Gaithersburg, MD, USA; Department of Psychiatry, Georgetown University Medical School, Washington, DC, USA.
Martínez J; Medical Department, Laboratorios Farmacéuticos ROVI, S.A., Calle Alfonso Gómez, 45-A, 28037 Madrid, Spain.
Anta L; Medical Department, Laboratorios Farmacéuticos ROVI, S.A., Calle Alfonso Gómez, 45-A, 28037 Madrid, Spain. Electronic address: lanta@rovi.es.
Naber D; Department of Psychiatry and Psychotherapy, Hamburg-Eppendorf University, Hamburg, Germany.
Correll CU; Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY, USA; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA; Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiat

Schizophr Res ; 246: 258-259, 2022 Aug.

Article in En | MEDLINE | ID: mdl-35853294

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Schizophr Res Journal subject: PSIQUIATRIA Year: 2022 Document type: Article Affiliation country: Ukraine

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google